Rafael Holdings, Inc. - 20 Oct 2023 Form 4 Insider Report for Cyclo Therapeutics, Inc. (CYTH)

Role: 10%+ Owner
Signature: /s/ William Conkling, CEO
Issuer symbol: CYTH
Transactions as of: 20 Oct 2023
Net transactions value: +$1,471,257
Form type: 4
Filing time: 23 Oct 2023, 06:08:02 UTC
Previous filing: 02 Aug 2023
Next filing: 13 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYTH	Common Stock	Exercise of in-the-money or at-the-money derivative security	$1,785,629	+2,514,970	+39%	$0.7100	9,029,940	20 Oct 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYTH	Warrant to Purchase Common Stock	Exercise of in-the-money or at-the-money derivative security	$314,371	-2,514,970	-100%	$0.1250	0	20 Oct 2023	Common Stock	2,514,970	$0.7100	Direct
transaction	CYTH	Warrant to Purchase Common Stock	Purchase		+2,766,467			2,766,467	20 Oct 2023	Common Stock	2,766,467	$0.9500	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 2,514,970 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised its Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants.

Content

The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 2,514,970 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised its Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants.